BioLife Solutions (NASDAQ: BLFS) grows Q1 2026 revenue 25%

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

BioLife Solutions reported strong first quarter 2026 results, led by revenue of $27.5 million, up 25% from Q1 2025. GAAP gross margin was 64%, while GAAP net income from continuing operations rose to $1.2 million, or $0.02 per diluted share. Adjusted EBITDA reached $6.2 million, representing 22% of revenue.

Cash, cash equivalents, and marketable securities totaled $111.5 million as of March 31, 2026. The company reiterated 2026 guidance for revenue of $112.5–$115.0 million, implying 17–20% growth, with gross margin in the mid‑60% range, GAAP net income for the full year, and continued expansion of adjusted EBITDA margin.

Positive

Strong top-line growth and profitability: Q1 2026 revenue reached $27.5 million, up 25% year over year, with GAAP net income from continuing operations of $1.2 million and adjusted EBITDA of $6.2 million (22% of revenue).
Reaffirmed double-digit growth outlook: 2026 revenue guidance of $112.5–$115.0 million implies 17–20% growth versus 2025, alongside mid‑60% gross margins, full-year GAAP net income, and continued expansion of adjusted EBITDA margin.

Negative

None.

Insights

BioLife delivered robust Q1 growth, returned to solid profitability, and reaffirmed healthy 2026 guidance.

BioLife Solutions posted Q1 2026 revenue of $27.5 million, up 25% year over year, with adjusted EBITDA of $6.2 million or 22% of revenue. GAAP net income from continuing operations improved to $1.2 million, reflecting operating leverage and higher other income.

GAAP gross margin was 64%, modestly lower than the prior year’s 67%, and adjusted EBITDA margin dipped from 24% to 22%, suggesting some mix or cost pressure even as scale benefits emerge. Cash, cash equivalents, and marketable securities were $111.5 million, providing ample financial flexibility.

The company reiterated 2026 guidance for revenue of $112.5–$115.0 million, implying 17–20% growth over 2025, with gross margins in the mid‑60% range and full‑year GAAP net income. Subsequent quarterly filings in 2026 will show how margins track against the targeted expansion in adjusted EBITDA.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q1 2026 revenue: $27.5 million GAAP gross margin: 64% GAAP net income from continuing operations: $1.2 million +5 more

8 metrics

Q1 2026 revenue $27.5 million Three months ended March 31, 2026; up 25% vs Q1 2025

GAAP gross margin 64% Q1 2026; compared with 67% in Q1 2025

GAAP net income from continuing operations $1.2 million Q1 2026; $0.02 diluted EPS

Adjusted EBITDA $6.2 million (22% of revenue) Q1 2026; vs $5.4 million (24% of revenue) in Q1 2025

Cash, cash equivalents, and marketable securities $111.5 million As of March 31, 2026

2026 revenue guidance $112.5–$115.0 million Represents 17–20% growth vs 2025 continuing operations

Biopreservation media clinical trial share ≈70% market share Used in ~250 ongoing commercially sponsored U.S. clinical trials

Commercial CGTs using BioLife media 17 therapies Number of unique commercial cell and gene therapies as of March 31, 2026

Key Terms

adjusted EBITDA, non-GAAP, discontinued operations, cell and gene therapy, +1 more

5 terms

adjusted EBITDA financial

"GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

non-GAAP financial

"BioLife is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP)."

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

discontinued operations financial

"presenting its financial condition and operating results as discontinued operations for all periods presented"

Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.

cell and gene therapy technical

"tools and services for the cell and gene therapy (“CGT”) market"

Therapies that use living cells or altered genes to treat or cure disease by repairing, replacing or reprogramming parts of the body; think of it as swapping or reprogramming malfunctioning hardware or software inside the body. Investors watch these treatments closely because they can command high prices and offer one-time or long-lasting benefits, but they also carry big development costs, complex manufacturing and regulatory risks that can cause large swings in a company’s value.

biopreservation media technical

"Healthy demand for our biopreservation media and growth across our broader product portfolio"

Biopreservation media are specially formulated liquids used to keep cells, tissues or biological samples alive and stable during storage and transport, like a refrigerated packing solution that prevents damage and decay. For investors, the quality of these media matters because they influence product shelf life, success of lab tests, regulatory acceptance, and logistics costs for therapies and diagnostics—factors that affect revenue, margins and market adoption.

Earnings Snapshot

Revenue: $27.5 million · Guidance included

Q1 2026

Revenue $27.5 million +25% YoY

GAAP net income from continuing operations $1.2 million

Adjusted EBITDA $6.2 million (22% of revenue)

GAAP gross margin 64%

Guidance

For 2026, the company guides to revenue of $112.5–$115.0 million (17–20% growth vs 2025 continuing operations), GAAP and adjusted gross margins in the mid‑60% range, full‑year GAAP net income, and continued expansion of adjusted EBITDA margin.

Understanding 8-K Material Events →

05/07/2026 - 04:14 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 7, 2026

BioLife Solutions, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36362

94-3076866

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3303 Monte Villa Parkway,

Bothell, WA 98021

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (425) 402-1400


N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


			o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

			o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

			o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

			o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of exchange on which registered
Common Stock, par value $0.001 per share	BLFS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On May 7, 2026, BioLife Solutions, Inc. (the “Company”) issued a press release announcing unaudited financial results and operational highlights for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.						Description
99.1						Press release, dated May 7, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	BioLife Solutions, Inc.

Date: May 7, 2026	By:	/s/ Troy Wichterman
		Name: Troy Wichterman
		Title: Chief Financial Officer

BioLife Solutions Reports First Quarter 2026 Financial Results

Total revenue of $27.5 million, up 25% over Q1 2025

GAAP gross margin and non-GAAP adjusted gross margin of 64%

GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue

Conference call begins at 4:30 p.m. Eastern time today

BOTHELL, Wash. (May 7, 2026) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (“CGT”) market, announces financial results for the three months ended March 31, 2026.

“We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million,” said Roderick de Greef, Chairman and Chief Executive Officer of BioLife Solutions. “Healthy demand for our biopreservation media and growth across our broader product portfolio reinforces our market leading position, while high-margin, recurring revenue drives a strong financial profile. Our products are embedded across a significant portion of commercial therapies and clinical pipelines, and we are seeing continued momentum across the CGT landscape including expansion into larger indications, encouraging data readouts, renewed funding activity and strategic M&A. This positions us well for the next phase of growth in this market and we remain confident in our full year outlook.”

First Quarter 2026 Business Highlights

•Our biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials in the U.S., representing a more than 70% market share. This includes over 30 Phase III trials, or nearly 80% of these late-stage trials. Our CellSeal vials and hPL products are used in over 35 clinical trials.

•Our biopreservation media is embedded in 17 unique commercial CGTs as of March 31, 2026, with expectations that approvals for 9 additional products, geographic expansions, earlier lines of treatment, or new indications will occur over the next 12 months. Our CellSeal cryogenic vials and hPL products are embedded in four approved therapies.

First Quarter 2026 Financial Results

BioLife is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife completed the divestiture of evo in 2025, and is presenting its financial condition and operating results as discontinued operations for all periods presented within the Unaudited Condensed Consolidated Balance Sheets and Unaudited Condensed Consolidated Statements of Operations. The Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) and Unaudited Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and


			Page 1

disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted.

REVENUE

•Total revenue for the first quarter of 2026 was $27.5 million, an increase of $5.4 million, or 25%, from $22.1 million for the first quarter of 2025 and up $2.7 million, or 11%, from the fourth quarter of 2025.

GROSS MARGIN

•Gross margin (GAAP) for the first quarter of 2026 was 64% compared with 67% for the first quarter of 2025. Adjusted gross margin (non-GAAP) for the first quarter of 2026 was 64% compared with 68% for the first quarter of 2025.

OPERATING INCOME / (LOSS)

•Operating income (GAAP) for the first quarter of 2026 was $27 thousand compared with an operating loss of $0.5 million for the first quarter of 2025. Adjusted operating income (non-GAAP) for the first quarter of 2026 was $1.0 million compared with $1.2 million for the first quarter of 2025.

NET INCOME

•Net income (GAAP) for the first quarter of 2026 was $1.2 million compared with $0.3 million for the first quarter of 2025. Adjusted net income (non-GAAP) for the first quarter of 2026 was $2.1 million compared with $2.0 million for the first quarter of 2025.

NET INCOME PER SHARE

•Net income per share (GAAP) for the first quarter of 2026 was $0.02 compared with $0.01 for the first quarter of 2025.

ADJUSTED EBITDA

•Adjusted EBITDA, a non-GAAP measure, for the first quarter of 2026 was $6.2 million, or 22% of revenue, compared with $5.4 million, or 24% of revenue, for the first quarter of 2025.

CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES

•Cash, cash equivalents, and marketable securities as of March 31, 2026, were $111.5 million.


			Page 2

(As a result of presenting amounts in millions, rounding differences may exist in the percentages above.)

2026 Financial Guidance

BioLife is reiterating its 2026 financial guidance as follows:

•Revenue of $112.5 million to $115.0 million, representing growth of 17% to 20% compared with 2025 revenue from continuing operations;

•Gross margin (GAAP) and adjusted gross margin (non-GAAP) in the mid-60% range;

•Net income (GAAP) for the full year; and

•Continued expansion of adjusted EBITDA margin (non-GAAP).

Conference Call & Webcast

Management will discuss the Company's financial results, provide a business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com for 90 days.

About BioLife Solutions

BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” “may,” “estimate,” “guidance,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or


			Page 3

circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included on a consolidated basis in this release: adjusted gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release.

We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information.

While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

Media & Investor Relations

At the Company

Troy Wichterman

Chief Financial Officer

(425) 402-1400

twichterman@biolifesolutions.com

Investors

Alliance Advisors IR

Jody Cain

(310) 691-7100

jcain@allianceadvisors.com


			Page 4

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)


	Three Months Ended March 31,
(In thousands, except per share and share data)		2026		2025

Revenue		$	27,500	$	22,054
Cost of revenue		10,004		7,254
Gross profit		17,496		14,800
Operating expenses:
General and administrative		12,208		11,351
Sales and marketing		2,526		2,443
Research and development		2,650		1,439

Intangible asset amortization		85		66
Total operating expenses		17,469		15,299
Operating income (loss)		27		(499)

Other income:
Interest income, net		1,041		683
Other income		180		101

Total other income, net		1,221		784

Income before income tax expense		1,248		285
Income tax expense		62		14
Net income from continuing operations		$	1,186	$	271

Discontinued operations:
Loss from discontinued operations before income tax expense		—		(719)
Income tax benefit		—		—
Loss from discontinued operations		$	—	$	(719)

Net income (loss)		$	1,186	$	(448)

Earnings per share - Basic:
Continuing operations		$	0.02	$	0.01
Discontinued operations		$	—	$	(0.02)
Net income (loss)		$	0.02	$	(0.01)
Earnings per share - Diluted:
Continuing operations		$	0.02	$	0.01
Discontinued operations		$	—	$	(0.01)
Net income (loss)		$	0.02	$	—
Weighted average shares used to compute net loss per share attributable to common shareholders:
Basic		48,458,536		47,134,720
Diluted		49,248,075		48,367,556


			Page 5

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)